Influence of GFI1^36N allele on progression. (A) Prognostic impact of GFI1^36N on disease progression of AML patients. GFI1^36S (homozygous for GFI1^36S) and GFI1^36N (heterozygous for GFI1^36N or homozygous for GFI1^36N; 1 patient only) de novo AML patients, recruited from the DSIL, had the same prognosis for a 5-year overall survival rate of approximately 27% (GFI1^36S) and 34% (GFI1^36N). Also, the 5-year relapse-free survival was not different between both groups (data not shown). (B) Genome-wide mRNA expression pattern of patients heterozygous for the GFI1^36N allele was not overall different from GFI1^36S-homozygous patients. Genome-wide RNA expression data were obtained by gene array analysis (Affymetrix) from a patient cohort from the HOVON study group analyzed in The Netherlands (Rotterdam; n = 350).